This page shows the latest Replagal news and features for those working in and with pharma, biotech and healthcare.
Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal
and Shire's Replagal (agalsidase alfa).
The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).
But even though catering for a small patient population (around 10, 000 people are thought to have the disorder globally), the firm has competition in Shire's Replagal (agalsidase alfa).
as Elaprase (idursulfase) for Hunter syndrome and Replagal (agalsidase alfa) for Fabry disease.
The company already had its own orphan brands such as Replagal (agalsidase alfa) for Fabry disease, Hunter's syndrome treatment Elaprase (idursulfase) and Vpriv (velaglucerase alfa) for Gaucher disease, when it
More from news
Approximately 2 fully matching, plus 15 partially matching documents found.
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...